ReceptivaDx is a first of its kind test for the detection of inflammation of the uterine lining most commonly associated with endometriosis, a leading cause of infertility and implantation failure.
Women testing positive for ReceptivaDx are 5 times less likely to succeed in IVF than women testing negative.
ReceptivaDxTM (BCL6 Test) Predicts Chances for a Successful Transfer and Successful Pregnancy
We are adding new IVF Centers every week to our list of sites where ReceptivaDx testing is offered. If you do not see a center close by, give us a call at (800) 795-5385 as some centers are not currently listed.
Victor Hugo is quoted as saying “Nothing is more powerful than an idea whose time...
Business Wire helped CiceroDx, Inc. to announce the publication of a new study that demonstrates...
Last week, ReceptivaDx joined many industry leaders at the American Society for Reproductive Medicine (ASRM)...
The ReceptivaDxTM Test was developed by CiceroDx in conjunction with Pathology Consultants, Inc. of Greenville, SC. Pathology Consultants, Inc. is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies. Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.
Copyright © 2020 ReceptivaDx™ | All Rights Reserved
